These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36205505)

  • 21. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M; Suzuki R; Nishida T; Shirane S; Shimazu Y; Minami Y; Mori T; Doki N; Kanda Y; Uchida N; Tanaka M; Ishikawa J; Togitani K; Fukuda T; Ichinohe T; Atsuta Y; Nagamura-Inoue T; Kiyoi H
    Intern Med; 2020; 59(16):1947-1956. PubMed ID: 32801269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
    Marcinek J; Plank L; Szépe P; Balhárek T
    Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
    Passamonti F; Thiele J; Girodon F; Rumi E; Carobbio A; Gisslinger H; Kvasnicka HM; Ruggeri M; Randi ML; Gangat N; Vannucchi AM; Gianatti A; Gisslinger B; Müllauer L; Rodeghiero F; d'Amore ES; Bertozzi I; Hanson CA; Boveri E; Marino F; Maffioli M; Caramazza D; Antonioli E; Carrai V; Buxhofer-Ausch V; Pascutto C; Cazzola M; Barbui T; Tefferi A
    Blood; 2012 Aug; 120(6):1197-201. PubMed ID: 22740446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
    Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
    Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
    Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
    Tefferi A; Barbui T
    Leukemia; 2013 Aug; 27(8):1617-20. PubMed ID: 23558521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
    Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
    Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
    Goulart H; Mascarenhas J; Tremblay D
    Ann Hematol; 2022 May; 101(5):935-951. PubMed ID: 35344066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
    Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
    Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
    Tam CS; Kantarjian H; Cortes J; Lynn A; Pierce S; Zhou L; Keating MJ; Thomas DA; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(33):5587-93. PubMed ID: 19786661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach.
    Rampotas A; Hargreaves R; McLornan DP
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101378. PubMed ID: 36333067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
    Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.